Evidence map›Paper›PMID 42214175›Full record

ReviewTranslational oncology2026

Current opinions on CEA in the diagnosis and prognosis of colorectal cancer.

Qi Han, Yajuan Zhu, Fangzhou Xing, Yun Xia

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qi HanDepartment of Clinical Laboratory, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266000, China.
Yajuan ZhuDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Fangzhou XingDepartment of General Surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266000, China.
Yun XiaDepartment of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. Electronic address: xiayun12cn@aliyun.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC), marked by high mortality and recurrence rate, poses a significant threat to public health. Differences in survival rates exist, with patients in CRC stage IV much worse than those in stage I and stage II. Carcinoembryonic antigen (CEA) has gained widespread use as a tumor marker for CRC. The method is easy to assess, inexpensive, noninvasive, with many advantages in monitoring the prognosis. However, its effectiveness in early detection of CRC leaves much to be desired. In this review, we summarized the current applications of CEA and discussed the innovative usage of CEA as a biomarker in CRC to facilitate a much more precise predictive and prognostic strategy. What's more, we concluded the biological features of CEA, involving its structure and gene regulation, and the roles of CEA in CRC progression and metastasis.

Indexed as

Carcinoembryonic antigenColorectal cancerDiagnosisPrognosis

Identifiers

PMID42214175
PMCPMC13242032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.